{"id":"padeliporfin-vtp","safety":{"commonSideEffects":[{"rate":"null","effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL4594284","moleculeType":"Small molecule","molecularWeight":"840.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Padeliporfin VTP works by accumulating in cancer cells and becoming activated by light of a specific wavelength, which then generates reactive oxygen species that damage and kill the cancer cells. This mechanism allows for targeted and selective destruction of cancer cells while minimizing damage to surrounding healthy tissue.","oneSentence":"Padeliporfin VTP is a photosensitizer that selectively targets and destroys cancer cells upon activation by light.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:21.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of metastatic liver cancer"}]},"trialDetails":[{"nctId":"NCT05919238","phase":"PHASE1","title":"Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Impact Biotech Ltd","startDate":"2024-05-15","conditions":"Locally Advanced Unresectable Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT04620239","phase":"PHASE3","title":"ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study","status":"RECRUITING","sponsor":"Steba Biotech S.A.","startDate":"2021-03-22","conditions":"Transitional Cell Cancer of Renal Pelvis and Ureter","enrollment":100},{"nctId":"NCT05918783","phase":"PHASE1","title":"Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer","status":"RECRUITING","sponsor":"Impact Biotech Ltd","startDate":"2025-05-28","conditions":"Peripheral Lung Tumor","enrollment":36},{"nctId":"NCT03315754","phase":"PHASE2","title":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Steba Biotech S.A.","startDate":"2017-10-02","conditions":"Localized Prostate Cancer","enrollment":50},{"nctId":"NCT04225299","phase":"PHASE3","title":"Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"Steba Biotech S.A.","startDate":"2020-03-31","conditions":"Localized Prostate Cancer","enrollment":""},{"nctId":"NCT01310894","phase":"PHASE3","title":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2011-02","conditions":"Prostate Cancer","enrollment":413},{"nctId":"NCT01021956","phase":"PHASE2","title":"Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD","status":"TERMINATED","sponsor":"Steba Biotech S.A.","startDate":"2010-06","conditions":"Macular Degeneration, Choroidal Neovascularization","enrollment":10},{"nctId":"NCT00707356","phase":"PHASE2","title":"Study of WST11 in Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2008-09","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT01875393","phase":"PHASE3","title":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2013-05","conditions":"Prostate Cancer","enrollment":81},{"nctId":"NCT00975039","phase":"PHASE2","title":"Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma","status":"TERMINATED","sponsor":"Steba Biotech S.A.","startDate":"2009-09","conditions":"Cholangiocarcinoma","enrollment":8},{"nctId":"NCT00975429","phase":"PHASE2","title":"Study Using WST11 in Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Steba Biotech S.A.","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":86},{"nctId":"NCT00974662","phase":"PHASE2","title":"Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Steba Biotech S.A.","startDate":"2009-09","conditions":"Non-Small Cell Lung Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["WST11"],"phase":"phase_3","status":"active","brandName":"padeliporfin VTP","genericName":"padeliporfin VTP","companyName":"Steba Biotech S.A.","companyId":"steba-biotech-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Padeliporfin VTP is a vascular targeted photodynamic therapy used to treat various cancers, including cholangiocarcinoma, peripheral lung tumor, prostate cancer, non-small cell lung cancer, and localized prostate cancer. Padeliporfin is a small molecule modality.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}